bit.bio

bit.bio’s proprietary gene-targeting platform opti-ox™ is applied to induce transcription factor combinations. This process facilitates the reprogramming of human induced pluripotent stem cells (iPSCs), which are then transformed into mature human cells and manufactured at scale with precision and consistency.

Its ioCells arm features a variety of cells (nerve cells, immune cells and muscle cells) and disease models for drug discovery and research purposes. The company recently unveiled the first project in a multi-year collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research.

The Cambridge University spin-out has raised over $200million in funding from investors including Arch Ventures, Charles River Laboratories, Foresite Capital, Milky Way, National Resilience, Tencent, Puhua Capital and more.

bit.bio’s illustrious board features serial entrepreneur Dr Hermann Hauser (chair) and Sir Gregory Winter, a winner of the Nobel Prize for Chemistry. The CEO and founder is Dr Mark Kotter.

Career opportunities at bit.bio